STING agonist-18 diTFA (compound 1a) is a small molecule linker-payload designed for constructing antibody-drug conjugates (ADCs), including Trastuzumab-based conjugates. It enables the study of targeted STING pathway activation in cancer immunotherapy research, applicable in both in vitro and in vivo experimental models.